BLADDER CANCER IN PATIENTS WITH TYPE 2 DIABETES TREATED WITH PIOGLITAZONE, A COMPARATIVE STUDY
AbstractBackground: This study was conducted to determine the frequency of bladder cancer in diabetic mellitus type II patients treated with Pioglitazone as compared with diabetic mellitus type II patients treated with other oral therapy or insulin therapy. Methods: It was a comparative; cross sectional survey in it 1,168 patients were selected from Medical and Endocrinology out-patient departments of Jinnah hospital, Lahore and a Periphery Diabetic using non-probability purposive sampling. Patients with Duration of Type 2 Diabetics more than or equals to 2 years, both male and female aged above or equal to 40 years were selected in the study. In Group A, type 2 diabetic patients taking Pioglitazones for ≥2yearswere selected and in group B type 2 Diabetic patients taking oral hypo-glycaemic or insulin were selected. The ethical committee of Allama-Iqbal Medical College, Lahore, approved this study. Results: Five hundred & eighty-four patients of Group A and 584 Patients of group B were selected in the study. In group A, 321 (54.97%) were male and 263 (45.03%) were female, whereas in group B 317 (54.28%) were male and 267 (45.72%) were female. Mean age of the group A patients was 47.01±8.27 years and mean age of group B patients was 58.97±8.14years. In group A mean duration of diabetes was 8.65±3.72 years and in group B the mean duration of diabetes was 10.86±4.48 years. Mean duration of Pioglitazone use was 6.92±2.28 years. Overall none of the patient was reported with the bladder cancer in the study. Conclusions: It is concluded from the study that none of the patient from either group was reported with bladder cancer haematuria and UTI. It is suggested that a randomized control trials should be conducted to single out the association of bladder cancer in patients with type II diabetes.Keywords: Diabetes mellitus; Pioglitazone; Bladder cancer; Pakistan
Ramachandran A, Snehalatha C, Shetty AS, Nanditha A. Trends in prevalence of diabetes in Asian countries. World J Diabetes 2012;3(6):110–7.
Siddiqui FJ, Avan BI, Mahmud S, Nanan DJ, Jabbar A, Assam PN. Uncontrolled diabetes mellitus: Prevalence and risk factors among people with type 2 diabetes mellitus in an Urban District of Karachi, Pakistan. Diabetes Res Clin Pract 2015;107(1):148–56.
Shera AS, Jawad F, Maqsood A. Prevalence of diabetes in Pakistan. Diabetes Res Clin Pract 2007;76(2):219–22.
Russell-Jones D, Cuddihy RM, Hanefeld M, Kumar A, Gonzalez JG, Chan M, et al. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study. Diabetes Care 2012;35(2):252–8.
Giovannucci E, Harlan DM, Archer MC, Bergenstal RM, Gapstur SM, Habel LA, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010;33(7):1674–85.
Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012;55(7):1953–62.
Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, et al. Risk of bladder cancer among diabetic patients treated with pioglitazone: Interim report of a longitudinal cohort study. Diabetes Care 2011;34(4):916–22.
Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, et al. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013;30(9):1026–32.
Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012;344:e3645.
Jenum A, Diep LM, Holmboe-Ottesen G, Holme I, Kumar B, Birkeland K. Diabetes susceptibility in ethnic minority groups from Turkey, Vietnam, Sri Lanka and Pakistan compared with Norwegians - the association with adiposity is strongest for ethnic minority women. BMC Public Health 2012;12(1):150.
Hirose H, Kawai T, Yamamoto Y, Taniyama M, Tomita M, Matsubara K, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 2002;51(3):314–7.
Chung JO, Cho DH, Chung DJ, Chung MY. Associations among Body Mass Index, Insulin Resistance, and Pancreatic β-Cell Function in Korean Patients with New-Onset Type 2 Diabetes. Korean J Intern Med 2012;27(1):66–71.
Yang XL, Chan JC. Diabetes, insulin and cancer risk. World J Diabetes 2012;3(4):60–4.
Colmers IN, Bowker SL, Majumdar SR, Johnson JA. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012;184(12):E675–83.
Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, et al. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012;104(18):1411–21.
Monami M, Dicembrini I, Mannucci E. Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials. Acta Diabetol 2014;51(1):91–101.